(Q44206796)

30 November 2017

title

Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites (English)

1 reference

30 November 2017

1 reference

Xue-Jun Zhao

1

1 reference

30 November 2017

D R Jones

2

1 reference

30 November 2017

Ying-Hong Wang

3

1 reference

30 November 2017

S W Grimm

4

1 reference

30 November 2017

S D Hall

5

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

30 November 2017

1 reference

30 November 2017

volume

32

1 reference

30 November 2017

issue

10

1 reference

30 November 2017

page(s)

863-878

1 reference

Statistical estimations in pharmacokinetics.

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F00498250210158230

Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250210158230

Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: substrate specificity with model substrates and promutagens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250210158230

Clinical pharmacokinetics-pharmacodynamics of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250210158230

The pharmacology and clinical uses of tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250210158230

Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250210158230

Covalent binding to apoprotein is a major fate of heme in a variety of reactions in which cytochrome P-450 is destroyed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250210158230

CYP3A4 drug interactions: correlation of 10 in vitro probe substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250210158230

Tamoxifen and the induction of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250210158230

The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250210158230

Characterization of the enzymatic and nonenzymatic peroxidative degradation of iron porphyrins and cytochrome P-450 heme

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250210158230

Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250210158230

Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250210158230

Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250210158230

Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250210158230

10.1080/00498250210158230

21 January 2018

Identifiers

DOI

1 reference

30 November 2017

1 reference